<PAGE> 1
As filed with the Securities and Exchange Commission on November 2, 1999
Registration No. 333-83989
================================================================================
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
----------------------
POST-EFFECTIVE AMENDMENT NO. 1 TO
FORM S-8
REGISTRATION STATEMENT UNDER
THE SECURITIES ACT OF 1933
----------------------
GENENTECH, INC.
(Exact name of registrant as specified in its charter)
<TABLE>
<S> <C>
Delaware 94-2345624
(State of Incorporation) (I.R.S. Employer Identification No.)
</TABLE>
1 DNA Way
South San Francisco, California 94080-4990
(Address of principal executive offices) (Zip Code)
----------------------
1999 Stock Plan
1991 Employee Stock Plan
(Full titles of the plans)
Stephen G. Juelsgaard, Esq.
Senior Vice President, General Counsel and Secretary
Genentech, Inc.
1 DNA Way
South San Francisco, California 94080-4990
(Name and address of agent for service)
(650) 225-1000
(Telephone number, including area code, of agent for service)
<TABLE>
<CAPTION>
CALCULATION OF REGISTRATION FEE
=======================================================================================================================
Proposed Maximum Proposed Maximum
Title of Securities Offering Aggregate Amount of
to be Registered Amount to be Registered Price per Share(1) Offering Price(1) Registration Fee(2)
- -----------------------------------------------------------------------------------------------------------------------
<S> <C> <C> <C> <C>
Common stock, par value 7,500,000 shares $99.30 $744,750,000 $211,335.60
$.02 per share
=======================================================================================================================
</TABLE>
(1) The Proposed Maximum Offering Price Per Share was estimated pursuant to
Rules 457(c) and 457(h) promulgated under the Securities Act of 1933, as
amended. Pursuant to Rule 457(h), in the case of an employee stock option
plan, the aggregate offering price is to be computed upon the basis of the
price at which the options may be exercised, or, if such price is not
known, upon the basis of the average of the high and low reported prices
pursuant to Rule 457(c). To be registered hereunder are 7,500,000 shares of
the common stock, par value $.02 per share, of Genentech, Inc., which are
referred to as the "Shares." Options covering 6,457,670 of the Shares have
been granted under the 1999 Stock Plan and have an option exercise price of
$97.00. Options covering 200,000 of the Shares have been granted under the
1991 Employee Stock Plan, and the weighted average exercise price of such
options is $51.11. The actual exercise price of each option was determined
with reference to the grant date of that option. The exercise price for the
options under the 1999 Stock Plan covering the remaining 842,330 Shares is
not known, and in accordance with Rule 457(c) was calculated with reference
to the high and low prices of July 26, 1999 reported on the New York Stock
Exchange of $126.00 and $130.75, respectively, the average of which is
$128.375. The Proposed Maximum Offering Price Per Share represents the
weighted average exercise price of the options covering the Shares, which
is $99.30.
(2) Previously paid.
<PAGE> 2
PART II: INFORMATION REQUIRED IN THE REGISTRATION STATEMENT
ITEM 3: INCORPORATION OF DOCUMENTS BY REFERENCE
In this Registration Statement, "Genentech," "we," "us" and "our" refer to
Genentech, Inc. The Securities and Exchange Commission, or SEC, allows us to
"incorporate by reference" the information we file with it, which means we can
disclose important information by referring to those documents. The information
included in the following documents is incorporated by reference and is
considered to be a part of this Registration Statement. The most recent
information that we file with the SEC automatically updates and supersedes more
dated information. We have previously filed the following documents with the SEC
and incorporate them by reference into this Registration Statement:
(a) Our annual report on Form 10-K for the year ended December 31, 1998;
(b) Our quarterly reports on Form 10-Q for the quarters ended March 31,
1999, June 30, 1999 and September 30, 1999;
(c) Our current report on Form 8-K dated June 28, 1999;
(d) Our current report on Form 8-K dated July 28, 1999; and
(e) The description under the heading "Description of Capital Stock"
relating to our common stock in the prospectus included in our Amendment No. 3
to the Registration Statement on Form S-3 (Registration No. 333-80601) filed
with the SEC on July 16, 1999, and the description under the heading
"Description of Capital Stock" relating to the common stock in the our final
prospectus filed with the SEC pursuant to Rule 424(b) under the Securities Act
of 1933, as amended, which is commonly known as the Securities Act, including
any amendment or report filed for the purpose of updating that description.
We also incorporate by reference all documents subsequently filed by us
pursuant to Section 13(a), 13(c), 14 or 15(d) of the Securities Exchange Act of
1934, as amended, which is commonly known as the Exchange Act, until all of the
shares registered under this Registration Statement are sold.
We will provide without charge to each person to whom a prospectus is
delivered, including any beneficial owner, a copy of any or all of the
information that has been incorporated by reference in this Registration
Statement. If you would like to obtain this information from us, please direct
your request to the Investor Relations Department, either in writing or by
telephone, to Genentech, Inc., 1 DNA Way, South San Francisco, California 94080,
Attention Investor Relations (650) 225-1260.
ITEM 4: DESCRIPTION OF SECURITIES
We have incorporated by reference the description under the heading
"Description of Capital Stock" relating to our common stock in the prospectus
included in our Amendment No. 3 to the Registration Statement on Form S-3
(Registration No. 333-80601) filed with the SEC on July 16, 1999, and the
description under the heading "Description of Capital Stock" relating to the
common stock in the our final prospectus filed with the SEC pursuant to Rule
424(b) under the Securities Act, including any amendment or report filed for the
purpose of updating that description.
ITEM 5: INTERESTS OF NAMED EXPERTS AND COUNSEL
Stephen G. Juelsgaard, Senior Vice President, General Counsel and Secretary
of Genentech, is an officer of Genentech and has received options under our 1999
Stock Plan and our 1991 Employee Stock Plan.
<PAGE> 3
ITEM 6: INDEMNIFICATION OF DIRECTORS AND OFFICERS
Our certificate of incorporation limits, to the fullest extent permitted by
Delaware corporate law, the personal liability of directors for monetary damages
for breach of their fiduciary duties.
Section 145 of the General Corporation Law of the State of Delaware (the
"DGCL") provides, in summary, that directors and officers of Delaware
corporations are entitled, under certain circumstances, to be indemnified
against all expenses and liabilities (including attorneys' fees) incurred by
them as a result of suits brought against them in their capacity as a director
or officer, if they acted in good faith and in a manner they reasonably believed
to be in or not opposed to the best interests of the corporation, and with
respect to any criminal action or proceeding, if they had no reasonable cause to
believe their conduct was unlawful; provided, that no indemnification may be
made against expenses in respect of any claim, issue or matter as to which they
shall have been adjudged to be liable to the corporation, unless and only to the
extent that the court in which such action or suit was brought shall determine
upon application that, despite the adjudication of liability but in view of all
the circumstances of the case, they are fairly and reasonably entitled to
indemnity for such expenses which the court shall deem proper. Any such
indemnification may be made by the corporation only as authorized in each
specific case upon a determination by the stockholders or disinterested
directors that indemnification is proper because the indemnitee has met the
applicable standard of conduct.
Our board of directors may provide similar indemnification to our officers,
employees and agents as it deems appropriate and as authorized by Delaware law.
We may purchase insurance on behalf of any director, officer, employee or agent
against any expense incurred by such person in his or her capacity.
Our certificate of incorporation also provides that Roche and the officers
or directors of Roche Holdings, Inc., or Roche, which is our majority
stockholder, will not be presumed liable to us or our stockholders for breach of
any fiduciary duty or duty of loyalty, failure to act in the best interests of
Genentech, or receipt of any improper personal benefit, simply because Roche or
any director or officer of Roche, in good faith, takes any action, exercises any
right or gives or withholds any consent with respect to any agreement or
contract between Roche and Genentech.
In addition, Roche will not be liable to us or our stockholders for breach
of any fiduciary duty if Roche pursues or acquires a potential corporate
opportunity of ours or does not inform us of a potential corporate opportunity.
If a director, officer or employee of Genentech who is also a director, officer
or employee of Roche knows of a potential transaction or matter that may be a
corporate opportunity both for Genentech and Roche, the director, officer or
employee is entitled to offer the corporate opportunity to us or Roche as the
director, officer or employee deems appropriate under the circumstances in his
or her sole discretion, and no such director, officer or employee will be liable
to us or our stockholders for breach of any fiduciary duty or duty of loyalty or
failure to act in our best interests or the derivation of any improper personal
benefit by reason of the fact that such director, officer or employee offered
such corporate opportunity to Roche (rather than to us) or did not communicate
information regarding such corporate opportunity to us, or Roche pursues or
acquires such corporate opportunity for itself or directs such corporate
opportunity to another person or does not communicate the corporate opportunity
to us.
Neither Roche nor any officer or director thereof shall be liable to us or
our stockholders for breach of any fiduciary duty or duty of loyalty or failure
to act in (or not opposed to) our best interests or the derivation of any
improper personal benefit by reason of the fact that Roche or an officer of
director thereof in good faith takes any action or exercises any rights or gives
or withholds any consent in connection with any agreement or contract between
Roche and Genentech. No vote cast or other action taken by any person who is an
officer, director or other representative of Roche, which vote is cast or action
is taken by such person in his capacity as a director of Genentech, shall
constitute an action of or the exercise of a right by or a consent of Roche for
the purpose of any such agreement or contract.
ITEM 7: EXEMPTION FROM REGISTRATION CLAIMED
Not applicable.
<PAGE> 4
ITEM 8: EXHIBITS
<TABLE>
<CAPTION>
EXHIBIT
NUMBER
<S> <C>
5 Opinion of Stephen G. Juelsgaard, Esq.
15.1 Letter re: Unaudited Interim Financial Information.(*)
23.1 Consent of Ernst & Young LLP, independent auditors.(*)
23.2 Consent of Stephen G. Juelsgaard, Esq. is contained in Exhibit 5 to
this Registration Statement.
24 Power of Attorney is contained on the signature pages.(**)
99.1 1999 Stock Plan.(*)
99.2 1991 Employee Stock Plan (as amended effective April 13, 1999).
- ------------------
</TABLE>
(*) Previously filed.
(**) Previously filed with respect to Arthur D. Levinson, Louis J. Lavigne, Jr.,
John M. Whiting, Franz B. Humer and Jonathan K.C. Knowles.
ITEM 9: UNDERTAKINGS
1. The undersigned registrant hereby undertakes:
(a) To file, during any period in which offers or sales are being made, a
post-effective amendment to this registration statement:
(i) To include any prospectus required by section 10(a)(3) of the
Securities Act;
(ii) To reflect in the prospectus any facts or events arising after
the effective date of the registration statement (or the most
recent post-effective amendment thereof) which, individually or
in the aggregate, represent a fundamental change in the
information set forth in the registration statement.
Notwithstanding the foregoing, any increase or decrease in
volume of securities offered (if the total dollar value of
securities offered would not exceed that which was registered)
and any deviation from the low or high end of the estimated
maximum offering range may be reflected in the form of
prospectus filed with the SEC pursuant to Rule 424(b) if, in the
aggregate, the changes in volume and price represent no more
than a 20% change in the maximum aggregate offering price set
forth in the "Calculation of Registration Fee" table in the
effective registration statement.
(iii) To include any material information with respect to the plan of
distribution not previously disclosed in the registration
statement or any material change to such information in the
registration statement;
Provided, however, that paragraphs (a)(i) and (a)(ii) do not apply if
the information required to be included in a post-effective amendment
by those paragraphs is contained in periodic reports filed by the
issuer pursuant to section 13 or section 15(d) of the Exchange Act
that are incorporated by reference herein.
<PAGE> 5
(b) That, for the purpose of determining any liability under the
Securities Act, each such post-effective amendment shall be deemed to
be a new registration statement relating to the securities offered
herein, and the offering of such securities at that time shall be
deemed to be the initial bona fide offering thereof.
(c) To remove from registration by means of a post-effective amendment any
of the securities being registered which remain unsold at the
termination of the offering.
2. The undersigned registrant hereby undertakes that, for purposes of
determining any liability under the Securities Act, each filing of the
registrant's annual report pursuant to Section 13(a) or Section 15(d) of
the Exchange Act (and, where applicable, each filing of an employee benefit
plan's annual report pursuant to section 15(d) of the Exchange Act) that is
incorporated by reference in the Registration Statement shall be deemed to
be a new registration statement relating to the securities offered herein,
and the offering of such securities at that time shall be deemed to be the
initial bona fide offering thereof.
3. Insofar as indemnification for liabilities arising under the Securities Act
may be permitted to directors, officers and controlling persons of the
registrant pursuant to the foregoing provisions, or otherwise, the
registrant has been advised that in the opinion of the SEC such
indemnification is against public policy as expressed in the Securities Act
and is, therefore, unenforceable. In the event that a claim for
indemnification against such liabilities (other than the payment by the
registrant of expenses incurred or paid by a director, officer or
controlling person of the registrant in the successful defense of any
action, suit or proceeding) is asserted by such director, officer or
controlling person in connection with the securities being registered, the
registrant will, unless in the opinion of its counsel the matter has been
settled by controlling precedent, submit to a court of appropriate
jurisdiction the question whether such indemnification by it is against
public policy as expressed in the Securities Act and will be governed by
the final adjudication of such issue.
<PAGE> 6
SIGNATURES
Pursuant to the requirements of the Securities Act of 1933, as amended, the
undersigned registrant certifies that it has reasonable grounds to believe that
it meets all of the requirements for filing on Form S-8 and has duly caused this
Post-Effective Amendment No. 1 to the Registration Statement to be signed on its
behalf by the undersigned, thereunto duly authorized, in the City of South San
Francisco, State of California, on November 2, 1999.
GENENTECH, INC.
By: /s/ CYNTHIA J. LADD
---------------------------------
Name: Cynthia J. Ladd
Title: Vice President, Corporate Law
and Assistant Secretary
<PAGE> 7
POWER OF ATTORNEY
KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature
appears below constitutes and appoints Arthur D. Levinson and Cynthia J. Ladd,
and each or any one of them, his true and lawful attorney-in-fact and agent,
with full power of substitution and resubstitution, for him and in his name,
place and stead, in any and all capacities, to sign any and all amendments
(including post-effective amendments) to this Post-Effective Amendment No. 1 to
the Registration Statement, and to file the same, with all exhibits thereto, and
other documents in connection therewith, with the Securities and Exchange
Commission, granting unto said attorneys-in-fact and agents, and each of them,
full power and authority to do and perform each and every act and thing
requisite and necessary to be done in connection therewith, as fully to all
intents and purposes as he might or could do in person, hereby ratifying and
confirming all that said attorneys-in-fact and agents, or any of them, or their
or his substitutes or substitute, may lawfully do or cause to be done by virtue
hereof.
Pursuant to the requirements of the Securities Act of 1933, this
Post-Effective Amendment No. 1 to the Registration Statement has been signed by
the following persons in the capacities and on the dates indicated.
<TABLE>
<CAPTION>
SIGNATURE TITLE DATE
<S> <C> <C>
* Principal Executive Officer and Director November 2, 1999
- -------------------------------------
Arthur D. Levinson
* Principal Financial Officer November 2, 1999
- -------------------------------------
Louis J. Lavigne, Jr.
* Principal Accounting Officer November 2, 1999
- -------------------------------------
John M. Whiting
Director
- -------------------------------------
Herbert W. Boyer
* Director November 2, 1999
- -------------------------------------
Franz B. Humer
* Director November 2, 1999
- -------------------------------------
Jonathan K.C. Knowles
Director
- -------------------------------------
Charles A. Sanders
/s/ MARK RICHMOND Director November 2, 1999
- -------------------------------------
Mark Richmond
*By: /s/ CYNTHIA J. LADD
- -------------------------------------
Cynthia J. Ladd
Attorney-in-fact
</TABLE>
<PAGE> 8
EXHIBIT INDEX
<TABLE>
<CAPTION>
EXHIBIT
NUMBER
<S> <C>
5 Opinion of Stephen G. Juelsgaard, Esq.
15.1 Letter re: Unaudited Interim Financial Information.(*)
23.1 Consent of Ernst & Young LLP, independent auditors.(*)
23.2 Consent of Stephen G. Juelsgaard, Esq. is contained in Exhibit 5 to
this Registration Statement.
24 Power of Attorney is contained on the signature pages.(**)
99.1 1999 Stock Plan.(*)
99.2 1991 Employee Stock Plan (as amended effective April 13, 1999).
</TABLE>
- ------------------
(*) Previously filed.
(**) Previously filed with respect to Arthur D. Levinson, Louis J. Lavigne, Jr.,
John M. Whiting, Franz B. Humer and Jonathan K.C. Knowles.
<PAGE> 1
EXHIBIT 5
November 2, 1999
Ladies and Gentlemen:
I am Senior Vice President, General Counsel and Secretary of Genentech, Inc.
(the "Company"). In connection with this opinion, I have examined the following
documents:
o the Company's Post-Effective Amendment No. 1 Registration Statement on
Form S-8, registration number 333-83989 (the "Registration Statement")
to be filed with the Securities and Exchange Commission covering the
offering of 7,500,000 shares of the Company's Common Stock, par value
$.02 per share (the "Shares"), pursuant to the Company's 1999 Stock
Plan and 1991 Employee Stock Plan (the "Plans") and the related
Prospectuses;
o the Company's Amended and Restated Certificate of Incorporation and
Bylaws; and
o such other documents, records, certificates, memoranda and other
instruments as I deem necessary as a basis for this opinion.
I have assumed the genuineness and authenticity of all documents submitted to me
as originals, the conformity to originals of all documents submitted to me as
copies thereof, and the due execution and delivery of all documents where due
execution and delivery are a prerequisite to the effectiveness thereof.
On the basis of the foregoing, and in reliance thereon, I am of the opinion that
the Shares, when sold and issued in accordance with the Registration Statement
and either of the Plans and the related Prospectus, will be validly issued,
fully paid, and nonassessable (except as to shares issued pursuant to certain
deferred payment arrangements, which will be fully paid and nonassessable when
such deferred payments are made in full).
I am admitted to practice only in the State of California. The opinions set
forth herein are limited to matters of the General Corporation Law of the state
of Delaware and the federal securities laws of the United States.
I consent to the filing of this opinion as an exhibit to the Registration
Statement.
Very truly yours,
/s/ STEPHEN G. JUELSGAARD
-----------------------------
Stephen G. Juelsgaard
Senior Vice President,
General Counsel and Secretary
<PAGE> 1
EXHIBIT 99.2
GENENTECH, INC.
1991 Employee Stock Plan
(As amended effective April 13, 1999)
1. Purpose
The purpose of this 1991 Employee Stock Plan (the "Plan") is to provide
employees of Genentech, Inc. (the "Company"), and its U.S. subsidiaries
designated by the Company's Board of Directors, who wish to become stockholders
of the Company an opportunity to purchase (i) shares of Callable Putable Common
Stock of the Company, or (ii) shares of Common Stock of the Company, to the
extent shares of Callable Putable Common Stock are converted to Common Stock in
accordance with the Company's Certificate of Incorporation (the shares referred
to in clauses (i) and (ii) above being hereinafter referred to collectively as
the "Shares"). The Plan is intended to qualify as an "employee stock purchase
plan" within the meaning of Section 423 of the Internal Revenue Code of 1986, as
amended (the "Code").
2. Eligible Employees
Subject to the provisions of Sections 7, 8 and 9 below, any individual who is in
the full-time employment of the Company on the day on which a Grant Date (as
defined in Section 3 below) occurs is eligible to participate in an offering of
Shares made by the Company hereunder. In addition, the Board of Directors may at
any time designate one or more of the Company's U.S. subsidiary corporations (as
defined in Section 425(f) of the Code) to be included in an offering of Shares
under the Plan. Full-time employment shall mean employment by the Company or its
designated U.S. subsidiary for:
(a) 20 hours or more per week; and
(b) more than five months in the calendar year.
3. Grant Dates
From time to time, the Board of Directors may fix a date (a "Grant Date") or a
series of dates (each of which is a "Grant Date") on which the Company will
grant rights to purchase Shares ("Rights") to employees eligible to participate.
4. Prices
The purchase price per Share for Shares covered by a grant of Rights hereunder
shall be determined by the Board of Directors, but in no event shall be less
than the lesser of:
(a) eighty-five percent (85%) of the fair market value of a Share on the Grant
Date on which such Right was granted; or
(b) eighty-five percent (85%) of the fair market value of a Share on the date
such Right is exercised as to that Share.
5. Exercise of Rights and Method of Payment
(a) Rights granted under the Plan will be exercisable on specific dates as
determined by the Board of Directors.
(b) The method of payment for Shares purchased upon exercise of Rights granted
hereunder shall be through regular payroll deductions or by lump sum cash
payment, or both, as determined by the Board of
1
<PAGE> 2
Directors. No interest shall be paid upon payroll deductions or other
payments in exercise of Rights unless specifically provided for by the
Board of Directors.
6. Terms of Rights
Rights granted hereunder shall be exercisable during a twenty-seven (27) month
period or such shorter period as determined by the Board of Directors. All
Rights granted to an employee shall terminate upon termination of full-time
employment of the employee. Any payments received by the Company from a
participating employee with respect to a Right granted hereunder and not
utilized for the purchase of Shares upon exercise of such Right shall be
promptly returned to such employee by the Company after termination of such
Right, except that amounts that were not so utilized because such amounts were
insufficient to purchase a whole Share may be applied toward the purchase of
Shares pursuant to a Right subsequently granted hereunder, if any.
7. Shares Subject to the Plan
No more than five million three hundred thousand (5,300,000) Shares may be sold
pursuant to Rights granted under the Plan. Appropriate adjustments in the above
figure, in the number of Shares covered by outstanding Rights granted hereunder,
in the exercise price of the Rights and in the maximum number of Shares which an
employee may purchase (pursuant to Section 9 below) shall be made to give effect
to any mergers, consolidations, reorganizations, recapitalizations, stock
splits, stock dividends or other relevant changes in the capitalization of the
Company occurring after the effective date of the Plan, provided that no
fractional Shares shall be subject to a Right and each Right shall be adjusted
downward to the nearest full Share. Any agreement of merger or consolidation
will include provisions for protection of the then existing Rights of
participating employees under the Plan. Either authorized and unissued Shares or
issued Shares heretofore or hereafter reacquired by the Company may be made
subject to Rights under the Plan. If for any reason any Right under the Plan
terminates in whole or in part, Shares subject to such terminated Right may
again be subject to a Right under the Plan.
8. Limitations on Grants
Anything to the contrary notwithstanding, pursuant to Section 423 of the Code:
(a) No employee shall be granted a Right hereunder if such employee,
immediately after the Right is granted, owns stock possessing five percent (5%)
or more of the total combined voting power or value of all classes of stock of
the Company, its parent corporation (as defined in Section 425(c) of the Code)
or any subsidiary corporation, in each case computed in accordance with Section
423(b)(3) of the Code.
(b) No employee shall be granted a Right which permits his Rights to purchase
Shares under all employee stock purchase plans of the Company and its
subsidiaries to accrue at a rate which exceeds twenty-five thousand dollars
($25,000) (or such other maximum as may be prescribed from time to time by the
Code) of fair market value of such Shares (determined at the time such Right is
granted) for each calendar year in which such Right is outstanding at any time,
all in accordance with the provisions of Section 423(b)(8) of the Code.
9. Limits on Participation
(a) Participation shall be limited to eligible employees who enroll under the
Plan.
(b) No Right granted to any participating employee shall cover more than twelve
thousand (12,000) Shares.
(c) No more than One Hundred Eighty Thousand (180,000) Shares may be purchased
during any calendar quarter upon the exercise of Rights granted under the Plan;
provided, however, that for those calendar quarters in which the Company pays
regular annual bonuses to eligible employees, the maximum aggregate numbers of
Shares which may be purchased upon the exercise of Rights shall be Two Hundred
Thousand (200,000) Shares. If the aggregate purchases of Shares upon exercises
of Rights granted under the Plan
2
<PAGE> 3
would exceed the applicable maximum number for a particular calendar quarter,
the maximum permitted number of Shares shall be allocated to the exercising
participants in proportion to the number of Shares they would otherwise purchase
during such calendar quarter.
10. Employee's Rights as Stockholder
No participating employee shall have any Rights as a stockholder in the Shares
covered by a Right granted hereunder until such Right has been exercised, full
payment has been made for the corresponding Shares and the purchase has been
entered in the records of the Transfer Agent for the Shares.
11. Rights Not Transferable
Rights under the Plan are not assignable or transferable by a participating
employee.
12. Amendments or Discontinuance of the Plan
The Board of Directors of the Company shall have the right to amend, modify or
terminate the Plan at any time without notice; provided, however, that the then
existing Rights of all participating employees shall not be adversely affected
thereby, except that in the case of a participating employee of a foreign branch
of the Company or a designated U.S. subsidiary corporation the Plan may be
varied to conform with local laws, and provided further that, subject to the
provisions of Section 7 above, no such amendment to the Plan shall, without the
approval of the stockholders of the Company:
(a) Increase the total number of Shares which may be offered under the Plan;
(b) Amend the Plan in any manner which would render Rights granted hereunder
unqualified for special tax treatment under Section 421 of the Code.
13. Effective Date and Approvals
The Plan shall become effective as of January 1, 1991. The Company's obligation
to offer, sell or deliver its Shares under the Plan is subject to the approval
of the Company's stockholders and any governmental approval required in
connection with the authorized issuance or sale of such Shares and is further
subject to the determination by the Company that all applicable securities laws
have been complied with.
14. Administration of the Plan
The Board of Directors or any committee or person(s) to whom it delegates its
authority (the "Administrator") shall administer, interpret and apply all
provisions of the Plan. The Administrator may waive such provisions of the Plan
as it deems necessary to meet special circumstances not anticipated or covered
expressly by the Plan. Nothing contained in this Section shall be deemed to
authorize the Administrator to alter or administer the provisions of the Plan in
a manner inconsistent with the provisions of Section 423 of the Code.
3
